PYC Therapeutics (PYC) is a clinical-stage biotechnology company at the forefront of developing a new generation of RNA therapies. Their mission is to create life-changing treatments for patients suffering from genetic diseases. PYC leverages its innovative drug delivery platform to significantly improve the effectiveness of these precision medicines. This platform tackles a major hurdle within the rapidly growing and commercially validated field of RNA therapeutics. PYC pioneered the journey of bringing a drug candidate for a childhood blinding eye disease into human trials, and they are now actively advancing multiple promising "fast-follower" programs towards clinical evaluation.